Genvoya (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide fumarate) for HIV

Overview
Genvoya is a prescription drug approved by the Food and Drug Administration (FDA) as a complete treatment regimen for HIV-1 infection. Genvoya is approved for use in people 12 years and older. Genvoya is a combination drug composed of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir alafenamide fumarate, which are also known respectively by the abbreviations EVG, COBI, FTC, and TAF. Elvitegravir is an antiviral medication of the integrase strand transfer inhibitor (INSTI) class. Cobicistat is a pharmacokinetic enhancer. Emtricitabine and Tenofovir disoproxil fumarate are both antiretroviral medications of the nucleoside reverse transcriptase inhibitor (NRTI) class. Cobicistat is believed to work by preventing the body from breaking down some antiretroviral drugs, increasing their effectiveness. The other three drugs are believed to work by preventing HIV from replicating in cells.

How do I take it?
Prescribing information states that Genvoya is taken once daily. Genvoya comes in tablet form.

Side effects
The FDA-approved label for Genvoya lists common side effects including nausea. Rare but serious side effects listed for Genvoya include lactic acidosis (a metabolic disorder), hepatomegaly (enlarged liver) with steatosis (fatty degeneration), severe exacerbation of Hepatitis B, kidney problems, and immune reconstitution syndrome.

For more details about this treatment, visit:

Genvoya highlights of prescribing information – Gilead

Overview of HIV Treatments – AIDS.gov